PI3K-gamma Inhibitors
1 drugsAbout PI3K-gamma
PI3K-gamma is a lipid kinase enzyme involved in cell signaling pathways that regulate cell growth, proliferation, survival, and migration. As a specific isoform of the PI3K family, it has a unique expression pattern making it an attractive therapeutic target.
PI3K-gamma is a drug target in oncology, though no genetic evidence currently links it to specific diseases. The existing drug approval highlights its relevance as a target, and inhibitors hold promise for advancing cancer treatment.
There is one FDA-approved drug, COPIKTRA (marketed by SECURA), that targets PI3K-gamma as a small molecule. It has two indications in oncology and was first approved in 2018.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 with only 1 trials.
- phase1 represents biological uncertainty with 50% completion.
Top PI3K-gamma Drugs
SECURA is the only company with an approved drug targeting PI3K-gamma.
Low competition represents an opportunity, but also a risk due to limited market validation.
PI3K-gamma Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PI3K-gamma, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation.
PI3K-gamma Clinical Trials 39 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 5 | 8 | 7 | 38% |
| Phase 2 | 15 | 7 | 4 | 3 | 64% |
| Phase 3 | 4 | 1 | 2 | 1 | 33% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved PI3K-gamma drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PI3K-gamma. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PI3K-gamma Drug Approval Timeline (2018 - 2018)
COPIKTRA was first approved in 2018 and remains the only approved drug.
The lack of recent approvals suggests potential saturation or challenges in targeting PI3K-gamma.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 39 clinical trials targeting PI3K-gamma.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities